Can Exercise During Chemo Ease Neuropathy? A Small Trial

Exercise during chemotherapy may help with the numbness, tingling, and pain of chemotherapy-induced peripheral neuropathy (CIPN), but the evidence is not ready to prescribe a single workout plan. A 2024 randomized pilot trial found preliminary symptom signals favoring a tailored walking and resistance program and explored whether exercise also changed brain networks that process bodily sensations. The clinical question matters because CIPN can persist for years, impair quality of life, and sometimes force changes to cancer treatment.

The intriguing part is not a decisive result. This was a small feasibility study: 19 patients were analyzed, and only 26 resting-state fMRI scans were usable across both study groups. Its value lies in testing a practical intervention during neurotoxic chemotherapy while asking a specific mechanistic question: could exercise influence both peripheral symptoms and the brain's representation of the body?

CIPN has few satisfying treatment options

CIPN can cause burning pain, reduced sensation, tingling, and trouble with balance or fine motor tasks. For people who develop persistent taxane-related neuropathy after breast cancer treatment, worse symptoms track with worse health-related quality of life. In a population-based study of 646 early-stage breast cancer survivors, moderate-to-severe symptoms were associated with clinically important impairment in quality-of-life measures for 29.5% to 93.3% of participants, depending on the symptom and domain assessed. The median time since taxane treatment was 3.6 years. Engvall et al.'s 2022 study cannot prove neuropathy caused every difference in quality of life, but it makes the burden hard to dismiss.

Duloxetine remains the drug with established evidence for reducing CIPN pain. A 2025 review of exercise and physiotherapy describes gabapentinoids as offering, at best, partial relief for this condition. That leaves room for non-drug approaches, especially those that patients can use alongside standard cancer care rather than instead of it. Tamayo Fajardo et al.'s 2025 systematic review places exercise and physiotherapy in that complementary role.

What the 2024 trial actually tested

Kleckner et al.'s 2024 randomized pilot trial enrolled patients beginning neurotoxic chemotherapy for breast, gastrointestinal, or multiple-myeloma cancers. Participants were insufficiently active at enrollment, defined as exercising on no more than two days per week. The study randomized them to 12 weeks of home-based, individually tailored, moderate-intensity progressive walking and resistance training or to an active control program of nutrition education.

The researchers assessed CIPN symptoms with the EORTC CIPN-20 questionnaire before, during, and after the intervention. They also measured tactile sensitivity with monofilaments and leg strength. Resting-state fMRI took place before and after the intervention to examine functional connectivity in the interoceptive brain system: networks involved in sensing and interpreting internal bodily signals.

The trial met its stated feasibility objective. Recruitment, retention, and adherence were sufficient to justify a larger trial. That result is clinically useful on its own. People receiving neurotoxic chemotherapy often face fatigue, symptoms, appointments, and disrupted routines; a program that cannot be carried out during treatment cannot help much outside a spreadsheet.

Preliminary efficacy signals on peripheral-neuropathy symptom measures favored exercise. The authors did not treat this 19-person trial as a definitive efficacy test. They reported standardized effect sizes, Cohen's d, rather than leaning on p-values that a study this small could not interpret reliably. The publication does not provide a decision-ready effect estimate with a confidence interval in the evidence available here, so it cannot tell a patient how much symptom improvement to expect.

The brain finding is a hypothesis, not proof

The imaging component gives the study its unusual angle. CIPN begins with injury and dysfunction in peripheral nerves, but pain and bodily discomfort are also processed by the central nervous system. Kleckner and colleagues examined whether the exercise and control groups showed different patterns of functional connectivity in interoceptive networks. Reported effect sizes suggested group differences, which the investigators presented as hypothesis-generating.

That is a reasonable question to ask, but a 26-scan fMRI dataset cannot answer it with much confidence. Functional-connectivity estimates can shift with noise, motion, analytic choices, and a few unusual participants. The study used a defined 3T Siemens MAGNETOM PrismaFit resting-state protocol lasting 7.5 minutes, which makes replication possible. It does not make the current connectivity signal stable.

Exercise can affect the brain in other populations, but those findings do not confirm a CIPN mechanism. A systematic review and meta-analysis in healthy adults found associations between cardiorespiratory fitness or exercise and white-matter measures. Maleki et al.'s 2022 review supports biological plausibility for neural effects of exercise, yet it studied healthy adults and brain structure rather than functional connectivity during chemotherapy. Those are related ideas, not interchangeable results.

Why exercise remains plausible despite the uncertainty

This pilot did not appear from nowhere. An earlier exploratory secondary analysis of 355 participants in the EXCAP exercise program found that six weeks of progressive walking and resistance training may ease hot/coldness and numbness/tingling in the hands and feet. Because CIPN was not the pre-registered primary endpoint in that analysis, it should support a future trial rather than settle the question.

The broader literature points in the same direction, with important qualifications. Amarelo et al.'s 2025 systematic review and meta-analysis synthesized randomized evidence on physical exercise for CIPN and reported positive signals. Tamayo Fajardo and colleagues likewise reviewed randomized exercise and physiotherapy studies. Both reviews flag major differences among interventions, including exercise type, intensity, duration, and study design. That heterogeneity prevents a standard prescription and leaves open the possibility that benefits differ by chemotherapy regimen, symptom severity, timing, or the type of training used.

Exercise also has support in neuropathic pain more broadly. A 2021 systematic review and expert consensus by Zhang et al. concluded that exercise benefits neuropathic pain across several causes. CIPN is one cause, not the whole category, so this evidence adds context rather than a direct treatment estimate. Similarly, exercise training improved heart-rate-variability measures in people with type 2 diabetes in a 2021 meta-analysis, but diabetic neuropathy and CIPN have different biology. Picard et al. offer an adjacent autonomic finding, not proof that exercise repairs chemotherapy-injured nerves.

What could make the early result look better than it is?

Small pilot trials often produce unstable effect sizes. This study was designed chiefly to establish feasibility, not to determine whether exercise reliably reduces CIPN. The participants also had to be able and willing to start a home exercise program while receiving chemotherapy. That may not reflect people with severe symptoms, profound fatigue, major mobility limits, or less support at home.

The intervention, EXCAP, is a proprietary program associated with the investigator group. That does not invalidate the work, but independent replication matters. Teams that did not develop the program should test a clearly described, non-proprietary version against an active comparison group. Researchers also need direct comparisons with options patients already encounter, such as duloxetine, cryotherapy, compression therapy, or lower-intensity movement programs. This study cannot rank exercise against any of them.

Real-world implementation is another obstacle. Cancer survivors treated with neurotoxic chemotherapy are less physically active than the general population, according to Mizrahi et al.'s 2023 study. A program can be safe and sensible yet still fail if pain, fatigue, transportation, cost, or uncertainty keep people from doing it.

What patients and clinicians can reasonably take from this

For a patient receiving neurotoxic chemotherapy, progressive walking and resistance training are worth discussing with the oncology team, especially when adapted to current symptoms, fall risk, blood counts, treatment schedule, and existing exercise experience. The trial supports feasibility and offers an early signal of benefit; it does not establish exercise as a replacement for symptom assessment, medication when appropriate, or dose-management decisions.

The next useful study would enroll enough patients to make CIPN the pre-registered primary endpoint, use validated symptom measures, include blinded outcome assessment, and report effect estimates with confidence intervals. A separate, larger imaging study would need roughly 80 to 100 usable scans before anyone should put much weight on the interoceptive-connectivity result. Until then, the honest conclusion is narrow: exercise during chemotherapy is a practical candidate for reducing CIPN symptoms, and the brain-based explanation remains an interesting question.